Literature DB >> 10869411

S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626.

M J Millan1, A Dekeyne, J M Rivet, T Dubuffet, G Lavielle, M Brocco.   

Abstract

The selective dopamine D(3)-receptor antagonist S33084 dose dependently attenuated induction of hypothermia by 7-hydroxy-2-dipropylaminotetralin (7-OH-DPAT) and PD128,907. S33084 also dose dependently reduced 7-OH-DPAT-induced penile erections (PEs) but had little effect on 7-OH-DPAT-induced yawning and hypophagia, and it did not block contralateral rotation elicited by the preferential D(3) agonist quinpirole in unilateral substantia nigra-lesioned rats. In models of potential antipsychotic activity, S33084 had little effect on conditioned avoidance behavior and the locomotor response to amphetamine and cocaine in rats, and weakly inhibited apomorphine-induced climbing in mice. Moreover, S33084 was inactive in models of potential extrapyramidal activity in rats: induction of catalepsy and prolactin secretion and inhibition of methylphenidate-induced gnawing. Another selective D(3) antagonist, GR218,231, mimicked S33084 in inhibiting 7-OH-DPAT-induced PEs and hypothermia but neither hypophagia nor yawning behavior. Similarly, it was inactive in models of potential antipsychotic and extrapyramidal activity. In distinction to S33084 and GR218,231, the preferential D(2) antagonist L741,626 inhibited all responses elicited by 7-OH-DPAT. Furthermore, it displayed robust activity in models of antipsychotic and, at slightly higher doses, extrapyramidal activity. In summary, S33084 was inactive in models of potential antipsychotic and extrapyramidal activity and failed to modify spontaneous locomotor behavior. Furthermore, it did not affect hypophagia or yawns, but attenuated hypothermia and PEs, elicited by 7-OH-DPAT. This profile was shared by GR218,231, whereas L741,626 was effective in all models. Thus, D(2)-receptors are principally involved in these paradigms, although D(3)-receptors may contribute to induction of hypothermia and PEs. S33084 should comprise a useful tool for further exploration of the pathophysiological significance of D(3)- versus D(2)-receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869411

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.

Authors:  Mark J Millan; Loretta Iob; Jean-Louis Péglion; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2006-09-19       Impact factor: 4.530

Review 2.  The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Authors:  Christian A Heidbreder; Eliot L Gardner; Zheng-Xiong Xi; Panayotis K Thanos; Manolo Mugnaini; Jim J Hagan; Charles R Ashby
Journal:  Brain Res Brain Res Rev       Date:  2005-07

3.  Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum.

Authors:  Daniel Marcellino; Sergi Ferré; Vicent Casadó; Antonio Cortés; Bernard Le Foll; Carmen Mazzola; Filippo Drago; Oliver Saur; Holger Stark; Aroa Soriano; Chanel Barnes; Steven R Goldberg; Carme Lluis; Kjell Fuxe; Rafael Franco
Journal:  J Biol Chem       Date:  2008-07-21       Impact factor: 5.157

4.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Authors:  István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

5.  D2 dopamine receptor subtype-mediated hyperactivity and amphetamine responses in a model of ADHD.

Authors:  Xueliang Fan; Ming Xu; Ellen J Hess
Journal:  Neurobiol Dis       Date:  2009-10-22       Impact factor: 5.996

6.  Effect of cyclosporin A on the uptake of D3-selective PET radiotracers in rat brain.

Authors:  Zhude Tu; Shihong Li; Jinbin Xu; Wenhua Chu; Lynne A Jones; Robert R Luedtke; Robert H Mach
Journal:  Nucl Med Biol       Date:  2011-03-03       Impact factor: 2.408

7.  Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus accumbens.

Authors:  Daniel F Manvich; Alyssa K Petko; Rachel C Branco; Stephanie L Foster; Kirsten A Porter-Stransky; Kristen A Stout; Amy H Newman; Gary W Miller; Carlos A Paladini; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2019-03-16       Impact factor: 7.853

Review 8.  Rationale in support of the use of selective dopamine D₃ receptor antagonists for the pharmacotherapeutic management of substance use disorders.

Authors:  Christian Heidbreder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-10-28       Impact factor: 3.000

9.  Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex.

Authors:  David J G Watson; Florence Loiseau; Manuela Ingallinesi; Mark J Millan; Charles A Marsden; Kevin C F Fone
Journal:  Neuropsychopharmacology       Date:  2011-10-26       Impact factor: 7.853

10.  CRH-stimulation of cyclic adenosine 5'-monophosphate pathway is partially inhibited by the coexpression of CRH-R1 and CRH-R2alpha.

Authors:  G Maya-Núñez; C Castro-Fernández; J P Méndez
Journal:  Endocrine       Date:  2005-06       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.